Consumers can buy Zepbound direct from the drugmaker if they'll pay out of pocket

Eli Lilly has noted a growing trend in direct-to-consumer sales of Zepbound, an obesity drug, with approximately 100,000 monthly purchases made via its LillyDirect platform. While the online availability offers customers significant discounts, the trade-off is that insurance coverage is largely not available. Patients need prescriptions, but the offering in vials is cheaper compared to traditional injector pens. This shift is compounded by increasing restrictions on insurance coverage for obesity-related medications, thus raising concerns about accessibility for those reliant on these drugs.

Every month, roughly 100,000 people buy Zepbound directly from Eli Lilly through its website, marking a significant trend in direct-to-consumer prescription medication sales.

It's a cultural phenomenon,

Read at www.npr.org